PREVAC: Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19: Coronavirus - COVID-19 - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
October 22, 2021 Newswires
Share
Share
Post
Email

PREVAC: Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19: Coronavirus – COVID-19

NewsRx COVID-19 Daily

2021 OCT 22 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx COVID-19 Daily -- Staff editors report on the newly launched clinical trial, NCT05075941, which has the following summary description: “The main objective of the study is to assess the level of vaccination coverage (VC) against COVID-19 among migrants, homeless and travelling community, according to their living conditions and housing. The secondary objectives are : - to compare the estimated level of vaccination coverage in the different sites and strata (emergency shelters/hotels, camps, workers’ hostels, on the street) with the estimated level in the general population of the same territory obtained from the French Health Insurance data (SIVAC). - identify the obstacles and leverage of vaccination (i.e. mobile team) according to living conditions and habitat (socio-demographic factors, personal health history, vaccine adherence, local health policies, etc.).”

As a matter of record, on October 14, 2021, NewsRx staff editors report that the available information provided by Epicentre on this trial include:

Tracking Information

Trial Identifier NCT05075941
First Submitted Date October 7, 2021
First Posted Date October 13, 2021
Results First Submitted Date Not Provided
Results First Posted Date Not Provided
Last Update Submitted Date October 7, 2021
Last Update Posted Date October 13, 2021
Primary Completion Date December 31, 2021
Start Date November 2021
Current Primary Outcome Measures •Vaccination coverage among COVID-19 [ Time Frame: one month ] -- Assess the proportion of people declaring to have received at least one dose of vaccination against COVID-19 among migrants, homeless and travelling community, according to their living conditions and housing
•Identify the most appropriate conditions for the use of vaccination against COVID-19 [ Time Frame: one month ] -- Promote interventions to encourage the use of COVID-19 vaccination
Current Secondary Outcome Measures Not Provided
Other Outcome Measures Not Provided
Change History Complete list of historical revisions of study NCT05075941

Descriptive Information

Brief Title Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19 Vaccination Program Among Populations in Very Precarious Situations
Official Title PREVAC: Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19
Brief Summary The main objective of the study is to assess the level of vaccination coverage (VC) against COVID-19 among migrants, homeless and travelling community, according to their living conditions and housing. The secondary objectives are : - to compare the estimated level of vaccination coverage in the different sites and strata (emergency shelters/hotels, camps, workers’ hostels, on the street) with the estimated level in the general population of the same territory obtained from the French Health Insurance data (SIVAC). - identify the obstacles and leverage of vaccination (i.e. mobile team) according to living conditions and habitat (socio-demographic factors, personal health history, vaccine adherence, local health policies, etc.).
Detailed Description Not Provided
Study Type Observational
Study Phase Not Provided
Study Design Observational Model: Other
Time Perspective: Cross-Sectional
Condition COVID-19
Intervention •Other: Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
Study Arms •Covid Homeless and migrants Marseille
Interventions:
⚬Other: Vaccination coverage
•Shelters Paris/93
Interventions:
⚬Other: Vaccination coverage
•Street/Camps Paris/93
Interventions:
⚬Other: Vaccination coverage
•Workers’ hostels Paris/93
Interventions:
⚬Other: Vaccination coverage
•travelling community IDF(77/93/95)
Interventions:
⚬Other: Vaccination coverage

Recruitment Information

Recruitment Status Not yet recruiting
Estimated Enrollment 3470
Estimated Completion Date February 2022
Primary Completion Date December 31, 2021 (Final data collection date for primary outcome measure)
Eligibility Inclusion Criteria:
•Adult (18 years and older)
•People considered as homeless (homeless, living in a camp or squat) or
•Living in adapted housing (migrant workers’ hostel) or
•Housed in residences of the National System or
•Housed in a social residence such as a 115 hotel or a social housing centre
•Freely and voluntarily consenting to participate Exclusion Criteria:
•Refusal to participate in the study (non-consent).
•Language barrier with no in-person or telephone translation available.
•Impossibility to give free and informed consent (comprehension barrier, cognitive and/or psychiatric and/or addictive disorders, external pressure from family and friends, persons under guardianship, etc.).
Sex/Gender Sexes Eligible for Study: All
Ages 18 years and older
Accepts Healthy Volunteers Not Provided
Contacts Primary contact: Thomas ROEDERER, +33 1 40 21 55 55, thomas.roederer@epicentre.msf.org
Backup contact: Jessica SAYYAD, +33 1 40 21 55 55, jessica.sayyad@epicentre.msf.org
Listed Location Countries Not Provided
Removed Location Countries

Administrative Information

NCT Number NCT05075941
Other Study ID Numbers 2021-A01960-41
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
Plan to Share Data Yes
Plan to Share Data (IPD) Description The results will be presented in a report to the Ministry of Health, the Haute Autorite de Sante and the various partners. The main findings of this study could potentially be compared with the findings of other ongoing studies, once they are completed. An abstract of the findings will be submitted for presentation at a scientific conference, and at least one manuscript will be submitted for publication in a peer-reviewed scientific journal.
Responsible Party Epicentre
Collaborators ⚬SANTE PUBLIQUE FRANCE
⚬Medecins Sans Frontieres, Netherlands
⚬Medecins du Monde
⚬CROIX ROUGE FRANCAISE
⚬OBSERVATOIRE DU SAMU SOCIAL
⚬INTERLOGEMENT 93
⚬Agence Regionale de Sante d’Ile de France
Investigators Principal Investigator: Elisabeth POULET, MD, Epicentre
Information Provided By Epicentre
Verification Date October 2021

(Our reports deliver fact-based news of research and discoveries from around the world.)

Older

Insurance, financial services giant The Hartford says workers to begin return to the office in December, in optimistic sign for downtown [Hartford Courant]

Newer

KKR Income Opportunities Fund Declares Monthly Distributions of $0.105 Per Share

Advisor News

  • I started using AI, but what now?
  • How to support an entrepreneur client with multiple businesses
  • Could a narrower focus help grow your practice?
  • U.S. debt hits $40 trillion: how to support concerned clients
  • Flourish brings private-bank-like cash solution to MassMutual’s network
More Advisor News

Annuity News

  • MassMutual Expands Lending Options With New Secured Credit Line
  • Corebridge Financial Introduces Progressive Trigger, a First-of-Its-Kind Index Annuity Strategy Designed to Turn Missed Years into Future Opportunity
  • Insurer proposes $1.1M deal to resolve CA teachers’ annuity fee lawsuit
  • IMOs get frustrated with slow carrier adoption of faster technology
  • New class-action lawsuit targets Delaware Life over annuity disclosures
More Annuity News

Health/Employee Benefits News

  • Minnesota seniors face tough choices for health plans
  • Recent Findings from New York University (NYU) Langone Health Provide New Insights into Managed Care (State Medicaid Body Mass Index Requirements for Solid Organ Transplant Coverage: A 50-State Policy Review): Managed Care
  • After booting 760K off ACA health plans, the Trump administration adds some people back
  • New Findings from University of Hawaii at Manoa in the Area of Science Reported (Expanded Medi-Cal Coverage and Persisting Access Barriers for Latino Immigrants in California): Science
  • What’s shaping retirement readiness in healthcare?
More Health/Employee Benefits News

Life Insurance News

  • Virginia orders Atlantic Coast Life to halt new business Nov. 1
  • AM Best Affirms Credit Ratings of China Taiping Insurance (Singapore) Pte. Ltd.
  • AM Best Upgrades Credit Ratings of Fidelity Life Association, A Legal Reserve Life Insurance Company; Affirms Credit Ratings of Industrial Alliance Insurance and Financial Services Inc. and Its Life/Health Subsidiaries
  • 777 Partners founder pleads guilty to $500 million fraud scheme
  • AM Best Affirms Credit Ratings of Luen Fung Hang Insurance Company Limited
Sponsor
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
  • Lauren Sinnott Named to Ragan’s Top Women in Marketing Awards, Class of 2026 
  • Classic Car Insurer OpenRoad Insurance Expands to 40 U.S. States in Two Years
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.